EUVIMEDEUVIMED entdecken
Crossref

Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis

Samuel Raimundo Fernandes iD, Sónia Bernardo, Sofia Saraiva, Ana Rita Gonçalves, Paula Moura Santos, Ana Valente, Luís Araújo Correia, Helena Cortez-Pinto iD, Fernando Magro iD

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad272 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Samuel Raimundo Fernandes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Propensity Score, Drug Monitoring. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few patients can reach transmural remission in Crohn’s disease (CD) with currently available therapies. Proactive optimization of infliximab (IFX) based on trough levels may potentially improve these results.

Methods

Retrospective cohort study including consecutive CD patients starting treatment with IFX. Rates of transmural remission were compared between patients with and without therapeutic drug monitoring (target level: 5-7 µg/mL). A propensity score–matched analysis was performed to adjust for potential confounders.

Results

A total of 195 CD patients were included, 57.9% receiving proactive therapeutic drug monitoring. The rates of transmural remission were higher in patients under proactive therapeutic drug monitoring (37.2% vs 18.3%; P = .004) with similar results in the propensity score–matched analysis (34.2% vs 17.1%; P = .025). In multivariate analysis, proactive therapeutic drug monitoring was independently associated with transmural remission (odds ratio, 2.95; 95% confidence interval, 1.44-6.06; P = .003).

Conclusions

Proactive optimization of IFX based on trough levels increases the rates of transmural remission in CD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseInfliximabPropensity ScoreDrug MonitoringRemission InductionGastrointestinal AgentsHumansRetrospective StudiesFemaleMaleAdultYoung AdultTreatment OutcomeFollow-Up StudiesMiddle Aged

Stichwörter der Autor:innen

Crohn's diseasetherapeutic drug monitoringtransmural remission

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal.
  • Clínica Universitária de Gastrenterologia da Faculdade de Medicina de Lisboa, Lisbon, Portugal.
  • Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii, Porto, Portugal.
  • CINTESIS@RISE, Faculty of Medicine, University of Porto, Porto, Portugal.

ORCID-Profile: Samuel Raimundo Fernandes, Helena Cortez-Pinto, Fernando Magro

Zitieren

APA

Fernandes, S. R., Bernardo, S., Saraiva, S., Rita Gonçalves, A., Moura Santos, P., Valente, A., Araújo Correia, L., Cortez-Pinto, H., & Magro, F. (2024). Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad272

Vancouver

Fernandes SR, Bernardo S, Saraiva S, Rita Gonçalves A, Moura Santos P, Valente A, et al. Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad272

BibTeX
@article{Fernandes2024,
  author = {Fernandes, Samuel Raimundo and Bernardo, Sónia and Saraiva, Sofia and Rita Gonçalves, Ana and Moura Santos, Paula and Valente, Ana and Araújo Correia, Luís and Cortez-Pinto, Helena and Magro, Fernando},
  title = {Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad272}
}
Kostenlos starten →